First Author | Hsieh WC | Year | 2018 |
Journal | Nat Commun | Volume | 9 |
Issue | 1 | Pages | 463 |
PubMed ID | 29386580 | Mgi Jnum | J:258478 |
Mgi Id | MGI:6114837 | Doi | 10.1038/s41467-018-02862-4 |
Citation | Hsieh WC, et al. (2018) IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells. Nat Commun 9(1):463 |
abstractText | X-linked lymphoproliferative syndrome type-2 (XLP-2) is a primary immunodeficiency disease attributed to XIAP mutation and is triggered by infection. Here, we show that mouse Xiap(-/-) regulatory T (Treg) cells and human XIAP-deficient Treg cells are defective in suppressive function. The Xiap(-/-) Treg cell defect is linked partly to decreased SOCS1 expression. XIAP binds SOCS1 and promotes SOCS1 stabilization. Foxp3 stability is reduced in Xiap(-/-) Treg cells. In addition, Xiap(-/-) Treg cells are prone to IFN-gamma secretion. Transfer of wild-type Treg cells partly rescues infection-induced inflammation in Xiap(-/-) mice. Notably, inflammation-induced reprogramming of Xiap(-/-) Treg cells can be prevented by blockade of the IL-6 receptor (IL-6R), and a combination of anti-IL-6R and Xiap(-/-) Treg cells confers survival to inflammatory infection in Xiap(-/-) mice. Our results suggest that XLP-2 can be corrected by combination treatment with autologous iTreg (induced Treg) cells and anti-IL-6R antibody, bypassing the necessity to transduce Treg cells with XIAP. |